Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
11.122 / 17.032
#88969

Re: Farmas USA

NVAX

5.24 ....glubs

"Buf, se me está haciendo más largo que un dia sin bolsa"

#88971

Re: Farmas USA

NVAX
Bueno me acabo de incorporar y visto la gráfica del día. Casi clavo el cierre de mayo.
Creo que esos gaps, al menos los primeros, si hay new de la gripe y es buena se quedan sin cerrar. El de 5,87 si que es posible que lo pueda cerrar en esta semana.

#88975

Farmas usa

Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules

BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 31, 2016) - Amarin Corporation plc (NASDAQ: AMRN) announced today that the U.S. Food and Drug Administration (FDA) has determined that Vascepa® (icosapent ethyl) capsules are eligible for five-year, new chemical entity (NCE), marketing exclusivity pursuant to the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. This determination provides Vascepa with the benefits of NCE exclusivity afforded by statute. NCE exclusivity for Vascepa runs from its date of FDA approval on July 26, 2012 and extends until July 26, 2017. The statutory 30-month stay triggered by patent litigation following generic application submissions permitted on July 26, 2016 would expire on January 26, 2020, seven-and-a-half years from FDA approval.

"Amarin's goal is to protect the commercial potential of Vascepa to 2030," stated John F. Thero, president and chief executive officer of Amarin. "NCE regulatory exclusivity complements multiple patents covering Vascepa with expiration dates in 2030."

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?